Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

201. Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis

Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis Transrectal ultrasound-guided prostate biopsies in patients taking aspirin for cardiovascular disease: a meta-analysis Carmignani L, Picozzi S, Bozzini G, Negri E, Ricci C, Gaeta M, Pavesi M CRD summary This review assessed whether continued aspirin therapy (...) was a risk factor for bleeding complications in patients undergoing ultrasound-guided biopsy of the prostate. The authors concluded that the treatment did not increase the risk of overall bleeding or moderate and severe haematuria. The unclear quality of this evidence precludes a confident assessment of the reliability of their conclusion. Authors' objectives To assess whether continued aspirin therapy was a risk factor for bleeding complications in patients undergoing ultrasound-guided biopsy

DARE.2011

202. Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after (...) percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S CRD summary Routine early tirofiban use plus aspirin and clopidogrel in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention may have reduced major adverse cardiovascular events without increasing major bleeding rates. The conclusions were not definitive due to limited

DARE.2011

203. Randomised controlled trial: In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding

Randomised controlled trial: In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In people with atrial fibrillation unsuitable for warfarin, apixaban reduces the risk of stroke compared with aspirin, with no difference in major bleeding Article

Evidence-Based Medicine (Requires free registration)2011

204. Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin

Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin Xie X, McGregor M Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Xie X (...) , McGregor M. Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin. Montreal: Technology Assessment Unit of the McGill University Health Centre (MUHC). Report no. 53. 2011 Authors' conclusions • The applicant intends to use the VerifyNow test to detect those patients at increased risk of arterial thrombotic events due to Clopidogrel resistance. Patients found to be clopidogrel resistant will be treated with other thienopyridine drugs. • The VerifyNow test is easy

Health Technology Assessment (HTA) Database.2011

205. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis

Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis Simpson SH, Gamble JM, Mereu L, Chambers T CRD summary The authors found insufficient data to confirm or dispute a dose relationship for aspirin in preventing cardiovascular events in people (...) with diabetes; further research was needed into aspirin use in the range 101mg to 325mg. Differences between the included studies and a lack of evidence for different aspirin dosage regimes mean that the authors' cautious conclusion is warranted. Authors' objectives To investigate the effect of aspirin dose on primary and secondary prevention of cardiovascular events in people with diabetes. Searching MEDLINE, EMBASE, The Cochrane Library (Issue 2, 2010), Web of Science, Science Citation Index, IPA

DARE.2011

206. Randomised controlled trial: Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding

Randomised controlled trial: Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding Article Text Therapeutics Randomised controlled trial Addition of omeprazole to dual

Evidence-Based Medicine (Requires free registration)2011

207. How soon to start: aspirin resumption after upper gastrointestinal bleed?

How soon to start: aspirin resumption after upper gastrointestinal bleed? How soon to start: aspirin resumption after upper gastrointestinal bleed? | Critical Care | Full Text Advertisement Search BioMed Central articles Search Impact Factor 4.950 Main menu Journal club critique Open Access How soon to start: aspirin resumption after upper gastrointestinal bleed? Rebecca Gooch and Marie Baldisseri Critical Care 2010 14 :331 DOI: 10.1186/cc9368 © BioMed Central Ltd 2010 Published: 20 December (...) 2010 Article details Evidence-Based Medicine Journal Club Edited by: Sachin Yende. University of Pittsburgh Department of Critical Care Medicine Extended abstract Citation Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, Leung VK, Wong VW, Chan FK. Ann Intern Med. 2010 Jan 5;152(1):1-9. Epub 2009 Nov 30. Background It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy

Critical Care - EBM Journal Club2011 Full Text: Link to full Text with Trip Pro

208. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.

Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. 21616527 2011 06 13 2011 06 21 2015 06 16 1474-547X 377 9782 2011 Jun 11 Lancet (London, England) Lancet Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. 2013-22 10.1016/S0140-6736(11)60600-4 Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent (...) stroke or other cardiovascular events. We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and cardiovascular ischaemic events in patients with a recent non-cardioembolic cerebral ischaemic event. This randomised, double-blind, parallel-group trial was undertaken in 802 centres in 46 countries. Patients who had an ischaemic stroke in the previous 3 months or a TIA in the previous 8 days were randomly allocated with a central

Lancet2011

209. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. 22036019 2011 12 19 2012 01 03 2016 11 22 1474-547X 378 9809 2011 Dec 17 Lancet (London, England) Lancet Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. 2081-7 10.1016/S0140-6736(11)61049-0 Observational studies report reduced colorectal cancer in regular (...) aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo. In the CAPP2 randomised trial, carriers of Lynch syndrome were randomly

Lancet2011 Full Text: Link to full Text with Trip Pro

210. Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke.

Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke. 20884870 2010 10 26 2010 11 16 2016 11 22 1524-4628 41 11 2010 Nov Stroke Stroke Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke. 2684-6 10.1161/STROKEAHA.110.586453 The combination of low-dose aspirin and dipyridamole is more effective than aspirin alone in reducing the risk of recurrent stroke and other major cardiovascular events in patients with a recent (...) transient ischemic attack or minor stroke. It is unknown whether this also applies to patients with a disabling stroke. We reanalyzed the data of 5700 patients from ESPRIT and ESPS-2 to study the effect of aspirin and dipyridamole according to modified Rankin scale (mRS) score at baseline. Primary outcome was vascular events (stroke, myocardial infarction, or vascular death). We used proportional hazards regression to estimate the treatment effect across mRS strata at baseline, and we tested for interactions

EvidenceUpdates2011

211. Aspirin in Alzheimer`s disease: increased risk of intracerebral hemorrhage: cause for concern?

Aspirin in Alzheimer`s disease: increased risk of intracerebral hemorrhage: cause for concern? 20930165 2010 10 26 2010 11 16 2016 11 22 1524-4628 41 11 2010 Nov Stroke Stroke Aspirin in Alzheimer's disease: increased risk of intracerebral hemorrhage: cause for concern? 2690-2 10.1161/STROKEAHA.109.576975 In a randomized controlled trial in Alzheimer's disease (AD), we found a higher number of intracerebral hemorrhages (ICHs) in patients randomized to aspirin treatment. Here, we evaluate (...) the literature on the risk of ICH as a complication in patients with AD treated with aspirin. Systematic review and comparison of the occurrence of events over time between the aspirin and control group in each trial using Cox regression analysis. Estimated hazard ratios (HRs) were combined in a pooled HR. Two randomized controlled trials on aspirin for AD were found. In the Evaluation of Vascular Care in Alzheimer's Disease (EVA) trial (conducted in our center), 4.6% of patients in the group receiving

EvidenceUpdates2011

212. Low-dose aspirin use and performance of immunochemical fecal occult blood tests.

Low-dose aspirin use and performance of immunochemical fecal occult blood tests. CONTEXT: Immunochemical fecal occult blood tests (iFOBTs) are potentially promising tools for colorectal cancer screening. Low-dose aspirin use, which increases the likelihood of gastrointestinal bleeding, is common in the target population for colorectal cancer screening. OBJECTIVE: To assess the association of low-dose aspirin use with the performance of 2 quantitative iFOBTs in a large sample of patients (...) undergoing colorectal cancer screening. DESIGN, SETTING, AND PARTICIPANTS: Diagnostic study conducted from 2005 through 2009 at internal medicine and gastroenterology practices in southern Germany including 1979 patients (mean age, 62.1 years): 233 regular users of low-dose aspirin (167 men, 67 women) and 1746 who never used low-dose aspirin (809 men, 937 women). MAIN OUTCOME MEASURES: Sensitivity, specificity, positive and negative predictive values, and area under receiver operating characteristic (ROC

JAMA2010

213. WITHDRAWN: Antihistamines versus aspirin for itching in late pregnancy.

WITHDRAWN: Antihistamines versus aspirin for itching in late pregnancy. BACKGROUND: While not common, itching in pregnancy (not due to liver disease) can be distressing. OBJECTIVES: The objective of this review was to assess the effects of treatment for itching in late pregnancy. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group trials register (January 2007). SELECTION CRITERIA: Randomised trials of treatments for itching in women in late pregnancy with normal liver (...) function. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trial quality and extracted data. MAIN RESULTS: One study of 38 women was included. This was a small crossover trial, using alternate allocation. The trial compared a histamine, chlorpheniramine, with aspirin. Aspirin was more effective than chlorpheniramine in relieving itching (odds ratio 2.39, 95% confidence interval 1.25 to 4.57). However, chlorpheniramine was more effective than aspirin when a rash was present

Cochrane2010

214. Prior aspirin use and outcomes in acute coronary syndromes

Prior aspirin use and outcomes in acute coronary syndromes 20946994 2010 10 15 2010 11 01 2016 11 25 1558-3597 56 17 2010 Oct 19 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Prior aspirin use and outcomes in acute coronary syndromes. 1376-85 10.1016/j.jacc.2010.06.028 The purpose of this study was to determine whether patients taking aspirin before an acute coronary syndrome (ACS) are at higher risk of recurrent events or mortality. Controversy exists whether prior (...) aspirin use is an independent predictor of worse outcomes in patients who experience an ACS. We evaluated 66,443 ACS patients from a merged database of previous Thrombolysis in Myocardial Infarction trials. We evaluated the differences in ACS type, total mortality, and the composite end point of death, myocardial infarction (MI), recurrent ischemia, or stroke between prior aspirin and nonprior aspirin users. We used multivariate analysis to control for differences in baseline characteristics. Prior

EvidenceUpdates2010

215. Aspirin use and the risk of gastric cancer: a meta-analysis

Aspirin use and the risk of gastric cancer: a meta-analysis Aspirin use and the risk of gastric cancer: a meta-analysis Aspirin use and the risk of gastric cancer: a meta-analysis Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, Wu XT CRD summary This review concluded that regular use of aspirin may be associated with a reduced risk of non-cardia gastric cancer, especially in Caucasian populations and those with Helicobacter pylori infection. The reliance on cohort and case control study designs (...) , some small sample sizes and potential publication bias may limit the reliability of the authors’ conclusion. Authors' objectives To evaluate the association between aspirin use and the risk of gastric cancer. Searching PubMed, EMBASE, and Academic Search Premier (EBSCO) databases were searched from 1950 to January 2009. Search terms were reported. Reference lists of reviews and retrieved articles were checked. Abstracts or unpublished reports were not considered. There were no language restrictions

DARE.2010

216. Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders

Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders Article Text Therapeutics Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders Free Valeria Mondelli , Carmine M Pariante Statistics from

Evidence-Based Mental Health2010

217. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis

Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, Wang K, Zou Y, Ge J CRD summary The authors concluded that aspirin did not significantly reduce the risk of cardiovascular events without an increase (...) in the risk of major bleeding in patients with diabetes. The reliability of these conclusions is uncertain given the potential for error and bias in the review methodology and the unclear quality of the included trials. Authors' objectives To assess the effect of aspirin therapy for primary prevention of cardiovascular events in patients with diabetes mellitus. Searching MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched up to June 2009 with no language

DARE.2010

218. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW CRD summary The authors concluded that daily aspirin reduced (...) deaths from several common cancers across different study populations and benefits increased with longer treatment duration. The authors' conclusions reflected the evidence presented and, despite some reporting limitations, are likely to be reliable. Authors' objectives To evaluate the effect of daily aspirin on the long-term risk of death due to cancer. Searching PubMed, EMBASE and Cochrane Database of Systematic Reviews were searched without language restrictions from 2002 to March 2010. Search

DARE.2010

219. Warfarin vs. Aspirin For Atrial Fibrillation Stroke Prevention

Warfarin vs. Aspirin For Atrial Fibrillation Stroke Prevention Warfarin vs. Aspirin For Atrial Fibrillation Stroke Prevention – TheNNTTheNNT Oral anticoagulants versus antiplatelet agents in non-valvular atrial fibrillation for stroke prevention (and no prior stroke) 60 for prevented stroke In Summary, for those who took warfarin instead of aspirin (for 1.9 years): Benefits in NNT 98.8% saw no benefit 1.6% were helped by preventing 1 stroke 0.3% were helped by avoiding a systemic embolism 1 (...) . The overall risk of stroke ranges from 2.5% to 4% per year. Both anti-platelet agents and oral anticoagulants reduce this risk, but both also increase the risk of hemorrhagic stroke and other bleeding. The review compared anti-platelet agents to anticoagulants in patients with atrial fibrillation but no history of stroke or transient ischemic attack. Eight randomized trials with 9598 subjects were included, with most examining warfarin versus aspirin (75 to 325 mg/day). The target INR range for subjects

theNNT2010

220. Aspirin For Major Heart Attack (STEMI)

Aspirin For Major Heart Attack (STEMI) Aspirin For Major Heart Attack (STEMI) – TheNNTTheNNT Aspirin Given Immediately for a Major Heart Attack (STEMI) 42 for mortality In Summary, for those who took the aspirin: Benefits in NNT 97.7% saw no benefit 2.3% were helped by being saved from death 1 in 42 were helped (life saved) Harms in NNT 0.6% were harmed by a minor bleeding event 1 in 167 were harmed (non-dangerous bleeding) *Blood levels showed anemia but not enough to require transfusion View (...) As: NNT % Source: Efficacy Endpoints: Death at 1 month following major heart attack (STEMI) Harm Endpoints: Major bleeding (brain bleeding or bleeding requiring transfusion) and minor bleeding. Narrative: The lone high quality trial addressing this question was multi-institutional across the U.S and Western Europe and was a randomized controlled trial of over 17000 subjects. Subjects were believed to be suffering acute MI by treating physicians and were randomized to aspirin, a thrombolytic (‘clot

theNNT2010